Motus GI Hosting Key Opinion Leader Call on Improving Endoscopy Outcomes with the Pure-Vu® System
Motus GI Holdings, Inc. (NASDAQ: MOTS) announced a key opinion leader (KOL) call scheduled for October 16, 2020, focusing on enhancing inpatient endoscopy outcomes with the Pure-Vu® system. Dr. Seth Gross from NYU Langone will address challenges in inpatient colonoscopy and discuss the benefits of the Pure-Vu system during the COVID-19 pandemic. The system, FDA-cleared for use, integrates with standard colonoscopes and is currently in over 20 U.S. hospitals, aiming to improve clinical outcomes and reduce hospital costs.
- The Pure-Vu system is FDA-cleared and focused on improving inpatient colonoscopy outcomes.
- The system is already implemented in over 20 major U.S. hospitals, indicating strong market adoption.
- The upcoming KOL call features an established expert, enhancing credibility and visibility for the Pure-Vu system.
- The press release does not provide specific financial metrics or sales figures, which may raise questions about revenue generation from the Pure-Vu system.
FORT LAUDERDALE, Fla., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it will host a key opinion leader (KOL) call on improving inpatient endoscopy outcomes with the Pure-Vu® system on Friday, October 16, 2020.
The webinar will feature a presentation by KOL Seth Gross, MD, NYU Langone, who will discuss:
- The unmet needs and challenges associated inpatient colonoscopy
- The benefits to patients in reducing time in the hospital, especially during the COVID-19 pandemic
- Mitigating increasing costs to hospitals due to delayed / incomplete procedures
Dr. Gross will be available to answer questions following the formal presentation.
Motus GI's management team will also provide an update on the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques. Within the last year, the Company initiated its commercial launch of the Pure-Vu System in the U.S. with an initial focus on inpatient colonoscopy. The system is currently in more than 20 major U.S. hospitals, including NYU Langone Medical Center, Cleveland Clinic, UC-Irvine Health, UCLA Health, University of Texas, Memorial Hermann and Geisinger Medical Center.
To register for the call, please click here.
Seth Gross, MD is Associate Professor of Medicine at the NYU Grossman School of Medicine and Clinical Chief of the Division of Gastroenterology & Hepatology at NYU Langone Health. As a gastroenterologist, Dr. Gross specializes in advanced endoscopic procedures. His clinical practice is focused on the prevention, diagnosis, and treatment of gastrointestinal pre-cancerous conditions and cancers, such as esophageal cancer, colorectal cancer, and pancreatic cancer. Dr. Gross’ research interests lie in the area of gastrointestinal malignancies as well as quality and innovation in endoscopy.
Dr. Gross oversees the clinical programming and quality initiatives for the Division of Gastroenterology & Hepatology at NYU Langone Health. He is a member of U.S. Multi-Society Task Force on Colorectal Cancer He is Chair of International Affairs Committee for the American College of Gastroenterology (ACG), reimbursement advisor to the American Medical Association for the ASGE, and an associate editor for the journal Gastrointestinal Endoscopy.
About Motus GI
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.
For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.
Investor Contact:
Bob Yedid
LifeSci Advisors
(646) 597-6989
bob@lifesciadvisors.com
FAQ
What is the purpose of the KOL call announced by Motus GI on October 16, 2020?
Who is presenting during the Motus GI KOL call?
Where is the Pure-Vu system currently being used?
What are the benefits of the Pure-Vu system mentioned in the PR?
